Open-label extension of the phase 3 Clarity AD trial in early Alzheimer's disease: participants on lecanemab continued to show clinical and quality-of-life benefit through 36 months, with early- vs delayed-start separation maintained and ARIA rates low after 6 months.
RCT
van Dyck et al. Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the clarity AD open-label extension study